Ali Amaal Abdulraqeb, Al Bostami Rouba D, Al-Othman Amani
Department of Chemical and Biological Engineering, American University of Sharjah P. O. Box 26666 Sharjah United Arab Emirates
Biomedical Engineering Graduate Program, American University of Sharjah P. O. Box 26666 Sharjah United Arab Emirates.
RSC Adv. 2024 Apr 2;14(15):10546-10559. doi: 10.1039/d4ra00410h. eCollection 2024 Mar 26.
Nano-based approaches, particularly nanogels, have recently emerged as a potential strategy for combating biofilm-related infections. Their exceptional characteristics including biocompatibility, biodegradability, stability, high water content, stimuli-responsiveness, and their nano size (which enables their penetration into biofilms) make nanogels a promising technology in the biomedical field. However, exploring nanogels for biofilm treatment remains in its early stages. This review examined the status of nanogels application for the treatment of bacterial biofilms. Recent investigations studied nanogels derived from natural polymers like chitosan (CS), hyaluronic acid (HA), and alginate, among others, for eliminating and inhibiting biofilms. These nanogels were utilized as carriers for diverse antibiofilm agents, encompassing antibiotics, antimicrobial peptides, natural extracts, and nanoparticles. Utilizing mechanisms like conventional antibody-mediated pathways, photodynamic therapy, photothermal therapy, chemodynamic therapy, and EPS degradation, these nanogels effectively administered antibiofilm drugs, exhibiting efficacy across several bacterial strains, notably (), (), and (), among others. Despite showing promise, nanogels remain relatively underexplored in biofilm treatment. This review concludes that research gaps are still present in biofilm treatment processes including (i) a better understanding of the stimuli-responsive behaviors of nanogels, (ii) active targeting strategies, and (iii) the narrow spectrum of antibiofilm agents loaded into nanogels. Hence, future studies could be directed towards the following elements: the exploration of multi-strain biofilms rather than single-strain biofilms, other endogenous and exogenous stimuli to trigger drug release, active targeting mechanisms, a broader range of antibiofilm agents when employing nanogels, and fostering more comprehensive and reliable biofilm treatment strategies. This review found that there are currently several research gaps as well in the use of nanogels for biofilm therapy, and these include: (i) very limited exogenous and endogenous stimuli were explored to trigger drug release from nanogels, (ii) the active targeting strategies were not explored, (iii) a very narrow spectrum of antibiofilm agents was loaded into nanogels, and (iv) only biofilms of single strains were investigated.
基于纳米的方法,尤其是纳米凝胶,最近已成为对抗生物膜相关感染的一种潜在策略。它们具有生物相容性、可生物降解性、稳定性、高含水量、刺激响应性以及纳米尺寸(这使其能够渗透到生物膜中)等卓越特性,使得纳米凝胶在生物医学领域成为一项有前景的技术。然而,探索纳米凝胶用于生物膜治疗仍处于早期阶段。本综述研究了纳米凝胶在治疗细菌生物膜方面的应用现状。最近的研究探讨了源自壳聚糖(CS)、透明质酸(HA)和藻酸盐等天然聚合物的纳米凝胶,用于消除和抑制生物膜。这些纳米凝胶被用作多种抗生物膜剂的载体,包括抗生素、抗菌肽、天然提取物和纳米颗粒。通过传统抗体介导途径、光动力疗法、光热疗法、化学动力疗法和胞外聚合物(EPS)降解等机制,这些纳米凝胶有效地递送抗生物膜药物,对多种细菌菌株显示出疗效,尤其是()、()和()等。尽管显示出前景,但纳米凝胶在生物膜治疗方面仍相对未得到充分探索。本综述得出结论,在生物膜治疗过程中仍存在研究空白,包括:(i)对纳米凝胶的刺激响应行为了解不足;(ii)缺乏主动靶向策略;(iii)负载到纳米凝胶中的抗生物膜剂谱较窄。因此,未来的研究可以针对以下方面:探索多菌株生物膜而非单菌株生物膜,触发药物释放的其他内源性和外源性刺激,主动靶向机制,使用纳米凝胶时更广泛的抗生物膜剂,以及制定更全面、可靠的生物膜治疗策略。本综述发现,目前在使用纳米凝胶进行生物膜治疗方面也存在几个研究空白,包括:(i)探索用于触发纳米凝胶药物释放的外源性和内源性刺激非常有限;(ii)未探索主动靶向策略;(iii)负载到纳米凝胶中的抗生物膜剂谱非常窄;(iv)仅研究了单菌株生物膜。